The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research aims to address the gap in the studies done and test the effects of a commercial mixture of 7 g of Arginine, 7 g Glutamine and 1.2 g HMB\* twice a day on hard to heal pressure ulcers in an Asian patient cohort in an acute healthcare setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of an Oral Mixture of Arginine, Glutamine and Beta-hydroxy-beta-methylbutyrate for Treatment of Pressure Ulcers

NCT03038490

Pressure Ulcers Stage III Pressure Ulcer, Stage IV

UNKNOWN NA

Nutritional Supplement on Wound Healing in Diabetic Foot

NCT03679273

Diabetic Foot

UNKNOWN NA

Plasma Activated Saline in Wound Treatment

NCT05924867

Wound Wound Infection Wound Heal

UNKNOWN NA

Novel Support Surface to Alleviate Pressure Ulcer

NCT04251897

Immobility Syndrome Pressure Ulcer Pressure Injury

COMPLETED NA

Wound Powder for Pressure Ulcers at End-of-life

NCT02008487

Pressure Ulcer Wounds

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pressure ulcers are defined as areas of localised damage to the skin, muscle or underlying tissue, caused by shear, friction or unrelieved pressure, usually over bony prominences. They are associated with many health conditions that cause prolonged bed rest, immobility, inactivity or poor sensation and can significantly contribute to morbidity and mortality, particularly in the aged population. International prevalence rates range widely from 4.6%- 83.6% due to methodological differences and classification systems. In Singapore, a study on the prevalence of pressure ulcers in 3 hospitals revealed a prevalence of 9% to 14%.

Pressure ulcers often fail to heal in a timely and orderly manner, resulting in a chronic non-healing wound. Many intrinsic and extrinsic factors have been identified that can disrupt the wound healing processes of haemostasis, inflammation, proliferation, angiogenesis and remodelling. One of the factors gaining more interest for its impact on wound healing processes is nutritional status.

Arginine is a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed during critical illness and severe trauma. There have been numerous research studies focusing on using arginine to enhance wound healing and pressure ulcer prevention. It is required for promotion of nitrogen balance, cell proliferation, T lymphocyte function and collagen accumulation. It also changes into nitric oxide, which is known for its vasodilatory and angiogenic properties.

Glutamine is conditionally essential amino acid because it can be manufactured in the body, but under extreme physical stress the demand for glutamine exceeds the body's ability to make it. Adequate amounts of glutamine are generally obtained through diet alone because the body is also able to make glutamine on its own. Certain medical conditions, including injuries, surgery, infections, and prolonged stress, can deplete glutamine levels. Since glutamine plays a key role in the immune system, a deficiency in this nutrient can significantly slow the healing process.

Beta-hydroxy-Beta methylbutyrate (HMB) is a metabolite of leucine, an essential amino acid. HMB supplementation was associated with increased muscle mass accretion. HMB appears to assert its effect via inhibiting muscle proteolysis and modulating protein turnover.

Recently, arginine has been found to accelerate wound healing in combination with HMB and glutamine. It was shown that healthy subjects who are supplemented orally with arginine had a significant rise in plasma arginine and ornithine levels that led to enhanced rate of collagen synthesis. In another recent study, a HMB/Arginine/Lysine mixture increased protein turnover in elderly patients over a year long period. However, there is no known randomised controlled trial done on patients with chronic hard to heal wounds in acute healthcare settings.

AIM To compare pressure ulcer healing rates in patients supplemented with a commercial HMB/Arginine/Lysine mixture (Abound) and standard high protein, high energy iso-nitrogenous medical nutritional supplements versus patients supplemented with only standard high protein, high energy iso-nitrogenous medical nutritional supplements.

OUTCOME INDICATORS

* Percentage change in wound size (length, depth, area)
* Percentage change in proportion of viable wound tissue (Refer to wound data collection for details)

The study will take on a comparative, randomised controlled trial design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pressure Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abound

Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)

Group Type EXPERIMENTAL

Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)

Intervention Type DIETARY_SUPPLEMENT

Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d

Placebo

Placebo comparator that contains none of the active ingredients

Group Type PLACEBO_COMPARATOR

Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)

Intervention Type DIETARY_SUPPLEMENT

Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)

Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pressure ulcers stage II, III or IV, non-healing admitted to Changi General Hospital for \> 2 weeks
* Patients who are able to attend outpatient follow-up appointments for dietary and wound review

Exclusion Criteria

* Age \< 21 years old
* Poorly controlled Diabetic Patients (HbA1c \>7.0%)
* Patients on Total Parenteral Nutrition
* Patients in MICU/ SICU/ Medically Unstable/ Palliative Care
* Patients with severe Sepsis
* Length of stay \< 2 weeks
* Patients who require fluid restriction \< 1L/d
* Patients on any other wound healing supplements (e.g. Zinc, Vitamin A and Vitamin C)
* Patients with lower extremity ulcers with untreated peripheral vascular disease
* Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue
* Patients unable to attend outpatient follow-up appointments
* Patients who cannot tolerate oral intake \> 70% EER and/or Fluid intake 30ml/kg BW
* Patients who require protein restriction
* Patients who are unable to give consent (absence of next-of-kin)

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No